|
|
June 2, 2008 Cambridge, MA - Seminar Abstracts |
 |
Events |
|
 |
| |
|
| Doc Edgarton Room Sessions |
9:00 -
9:45 AM |
Achieving Higher Speed and Resolution with Ascentis
Express Fused-Core HPLC Columns . . . extend the value of traditional instruments.
Ascentis Express® Fused-Core™ HPLC technology is a modern “ultra-high
performance” particle in which a 0.5 micron outer shell of porous
silica is fused to a solid 1.7 micron core. This permits greater efficiencies
and faster separations compared to 3 micron or larger porous particles,
and allows operating pressures that can be well within the range of traditional
HPLC instruments. Column efficiencies are comparable to porous particles
in the 1.7-1.8 µm range, but pressures are much lower. Retention factors
and sample capacity are comparable to porous particles. Long-lasting Ascentis
Express columns extend the practical lifetime of traditional HPLC instruments
and make new, ultra-HPLC instruments even more valuable by permitting the
use of longer columns (more plates and resolution) and higher flows (more
speed).
New applications of Ascentis Express will be shown with short columns for
fast LC and LC-MS and with coupled columns for very high resolution. Greater
than 100,000 plates can be achieved for difficult separations such as peptides
and deuterium isotopes. Techniques will be described for calibrating traditional
HPLC instruments and optimizing them for use with new Fused-Core particle
technology. |
9:45 -
10:15 AM |
Basics of Chiral HPLC, Definitions, Principles &
CSPs Available
This presentation will begin with a basic overview of stereochemistry
classification, chromatographic principles and nomenclature.We will then
explore the chromatographic challenges of chiral separations through various
stages of drug development. The major classes of chiral stationary phases
(CSPs) are introduced and their chemistry and chiral selectivity are described.Results
are presented for the screening of analytes using four CHIROBIOTIC™
and four CYCLOBOND™ CSPs in up to four different mobile phase types
based on methods development screening procedures developed at Astec. The
analytes chosen have been classified by the pharmaceutical industry as racemic
switches. |
10:30 -
11:45 AM |
High Throughput Method Development Strategies &
Results for Various Classes of Racemic Switches
The objective of an initial high-throughput screen is to obtain at
least partial separation of as many analytes as possible, and to then identify
the best CSP and mobile phase conditions for further optimization. In a
blind screen, the broad-based selectivity and complimentary nature of the
CHIROBIOTIC and CYCLOBOND CSPs, when used with one or more methods development
protocols, developed by Astec, provides for a high degree of success. Choosing
a CSP and mobile phase for the primary screen often begins with whether
the analyte is chiral acid, base or neutral. After screening, optimization
protocols developed by Astec help determine the best conditions for resolution
of enantiomers, and the parameters for manipulating elution order and time.
Baseline separation in the optimized system is a minimal requirement for
success. |
| Campton Room Sessions |
9:00 -
10:45 AM |
Understanding Karl Fischer Titration
The Karl Fischer titration
is the most versatile and generally accepted analytical method for determining
water content. It is independent of the sample’s state of matter and
is therefore suitable for the analysis of solids, liquids, and gases. Critical
to the accurate determination of water content is that the sample be soluble
in the solvent mixture, the working pH of the system is not affected by
the sample, and side reactions are avoided. |
11:00 -
12:00 PM |
MISSION™ RNAi Tools: Effective Gene Silencing
RNA interference methodologies have emerged as extremely effective tools
for dissecting and understanding gene function. Both synthetic siRNA and
vector-based shRNA have been successfully used to administer gene silencing.
In this presentation, we will address the following:
· Comprehensive Knockdowns using Mission siRNA/shRNA
· TRC (The RNAi Consortium)
overview & functional validation of shRNA clones
· Rapid
screening to identify biomarkers in chemotherapy drug response
·
Novel tool for enhanced transduction efficiency
· New collection
of Validated Antibodies to complement knockdown studies. |
|
|
 |
|
|
|
